Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054207 | 0.87 | BACE1 (0.51) | OPRD1OPRM1BACE1BACE2 | |
| SCHEMBL29375248 | 0.85 | OPRD1 (0.57) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL9390903 | 0.83 | CTSC (0.59) | CTSC | |
| SCHEMBL2183443 | 0.83 | CTSC (0.55) | CTSCOPRD1OPRM1OPRK1BACE1 | |
| SCHEMBL29375819 | 0.82 | OPRM1 (0.54) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL4086489 | 0.80 | OPRD1 (0.46) | CTSCOPRD1OPRM1OPRK1ACE | |
| SCHEMBL29674783 | 0.80 | OPRM1 (0.53) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL27915852 | 0.79 | OPRL1 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL677176 | 0.79 | GLP1R (0.43) | OPRD1OPRM1OPRK1 | |
| SCHEMBL3125104 | 0.79 | GLP1R (0.43) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CTSC 383/4885OPRD1 3859/4885OPRM1 3352/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CTSC 383/4885OPRD1 3859/4885OPRM1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.